"But the really important thing that we showed was that there is no evidence that these medications might increase the severity of COVID-19 or risk of death.
"On the contrary, we found that there was a significantly lower risk of death and critical outcomes, so they might in fact have a protective role—particularly in patients with hypertension.
"COVID-19 patients with high blood pressure who were taking ACEi/ARB medications were 0.67 times less likely to have a critical or fatal outcome than those not taking these medications.
